The Government of India has introduced new trade-margin controls for 137 identified non-scheduled anti-cancer drugs in a move intended to improve affordability and reduce the financial burden of cancer treatment.
The National Pharmaceutical Pricing Authority, operating under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers, issued the notification on October 17, 2026. The measure invokes Paragraph 19 of the Drugs (Prices Control) Order, 2013, which allows government intervention in drug prices under specified circumstances.
Editorial Insight
Key Highlights
Important points readers should notice.
Issue/Event: Trade-margin rationalisation for 137 identified non-scheduled anti-cancer drugs.
Location: India.
Authority/Organisation: National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
Action Taken: The government notified a 30% trade-margin cap under the prescribed pricing framework for covered medicines and directed manufacturers to submit revised prices.
Impact: Revised prices are scheduled to take effect on November 9, 2026, with potential MRP reductions of up to 70% for affected products, depending on existing price structures.
Under the notification, trade margins for the covered anti-cancer formulations will be restricted to 30% under the prescribed pricing framework. The government expects the intervention to reduce the maximum retail prices of affected medicines by as much as 70%, although the actual reduction will vary according to existing prices and the applicable calculation.
The revised prices are scheduled to become effective on November 9, 2026. The announcement does not mean that every cancer medicine sold in India will become cheaper by 70%. The intervention applies to the specified medicines and formulations covered by the notification, and the final price reduction will depend on each product's existing price structure.
Which Cancer Medicines Are Covered?
Editorial Analysis
Why This Matters
The cost of cancer treatment can place significant financial pressure on patients and their families, particularly when treatment requires expensive specialised medicines over an extended period. By introducing controls for 137 identified anti-cancer drugs, the government is attempting to reduce excessive trade margins and improve affordability for patients using the covered medicines. The measure could also improve price transparency by requiring manufacturers, retailers and hospitals to make revised prices available. Patients will be better positioned to compare the applicable prices and identify potential overcharging once the new rates take effect. However, the scale of the benefit will vary across medicines. The expected reduction of up to 70% is not a blanket promise for all cancer medicines or every patient's total treatment bill.
The notification covers 137 identified non-scheduled anti-cancer drugs recommended for inclusion following an expert review. The list includes medicines used in several areas of cancer treatment, including immunotherapy and other specialised therapies.
Medicines specifically highlighted in the government's announcement include pembrolizumab, durvalumab and osimertinib. The broader list also covers drugs such as denosumab, pegfilgrastim and bevacizumab, which are used in different cancer-related treatment settings.
The inclusion of these medicines is significant because certain specialised anti-cancer treatments can involve substantial expenditure over a course of therapy. The cost burden may include medicines, diagnostic tests, hospital visits, administration charges and other treatment-related expenses.
However, the notification does not establish a single uniform price for all products or all treatment regimens. Patients and caregivers will need to consult the revised price lists for the exact medicine, formulation, strength and brand they use.
Why Has the Government Introduced the Price Controls?
The government said the intervention aims to address excessive trade margins, make cancer treatment more affordable and improve access to anti-cancer medicines.
Trade margins represent the difference between a product's acquisition cost and its subsequent selling price within the distribution chain. Where margins are high, the price paid by patients may substantially exceed the initial price at which a medicine enters distribution.
The new framework seeks to limit the permitted margin under the prescribed calculation and establish revised maximum retail prices for the covered formulations. The notification applies to specified non-scheduled anti-cancer medicines, including covered patented drugs, rather than only a narrow group of older generic medicines.
The regulator's decision followed recommendations from an expert committee constituted under the Directorate General of Health Services. The committee considered medicines for inclusion based on the government's affordability and public-health objectives.
The measure builds on an earlier trade-margin rationalisation exercise introduced in 2019, when controls were applied to 42 selected non-scheduled anti-cancer medicines. According to the government, that initiative resulted in reductions of up to 90% in the MRPs of 526 brands.
The 2026 notification expands the approach to a larger set of medicines. Its practical effect will depend on implementation, revised product prices and compliance by manufacturers, distributors, pharmacies and hospitals.
When Will the Revised Prices Apply?
The revised prices are scheduled to take effect on November 9, 2026.
Manufacturers have been directed to inform the NPPA of their revised prices within seven days of the notification's publication. They must also make the revised price information available and communicate it to relevant retailers and hospitals.
Pharmacies and hospitals will be required to charge the revised prices from the implementation date and display the applicable prices at their establishments. Hospitals must also prominently display the revised prices on their websites, as required by the notification.
The requirements are intended to make the revised rates visible to patients and healthcare providers, helping them identify the prices that apply to the covered medicines.
Patients should not assume that every pharmacy or hospital will immediately apply a lower price before the notified implementation date. They should check the official revised price list and verify the price of their exact medicine once the new rates take effect.
How Much Could Patients Save?
The government expects MRPs of the identified medicines to fall by up to 70%, depending on their existing price structures. This is an estimate of the potential reduction for affected products, not a guarantee that every covered medicine will experience the same decrease.
The actual savings for an individual patient will depend on the medicine prescribed, its existing retail price, the revised price, the quantity required and the duration of treatment.
For example, a patient purchasing a medicine whose revised MRP falls substantially could see a meaningful reduction in medicine expenditure. Another patient using a different covered medicine may experience a smaller reduction. Patients whose medicines are not included in the notification should not assume that the new controls automatically change their prices.
Cancer treatment expenses also extend beyond medicine costs. Hospital charges, consultations, tests, procedures and other services may remain separate components of the overall bill.
The notification therefore represents a targeted intervention in the pricing of specified anti-cancer medicines rather than a universal cap on every expense associated with cancer treatment.
How Can Patients Check the New Prices?
The NPPA has directed manufacturers to publish and communicate revised price information. Retailers and hospitals are also required to display the applicable revised prices under the implementation framework.
Consumers can consult the NPPA's official website and its Pharma Sahi Daam application to check medicine-price information.
Patients should compare the exact formulation, strength, dosage form and brand details before concluding that a price is incorrect. If a covered medicine continues to be sold above the applicable permitted price after November 9, patients can seek clarification from the pharmacy or hospital and use the regulator's official grievance and information channels.
The implementation will require coordination among manufacturers, distributors, retailers, hospitals and regulatory authorities. Clear price displays and accurate product identification will be important to ensure that patients receive the intended benefit.
The government has also indicated that the covered list may be updated periodically in response to market developments and public-health considerations. This leaves room for future review as the regulator evaluates the medicine market and the effects of the new controls.
